ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC) announced the selection of PCT, LLC, a subsidiary of Caladrius Biosciences, Inc., as the US manufacturer for ImmunoCellular’s …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the first quarter 2015. “During the first quarter, we strengthened our Company’s financial standing, advanced …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in today with a few insights on ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC), after the company reported full-year 2014 results, posting EPS of …
ImmunoCellular Therapeutics (NYSE:IMUC) announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at …
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE:IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the …
In a research report published Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4.00 price …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4 price target, …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $3 price target, as the company presented updated Phase II …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE :IMUC) with a price …
